Janssen Biotech, Inc.

Centocor Ortho Biotech Inc.

Centoco Ortho Biotech Inc.

Linus Hyun

Karyn O'Neil

Steven Jacobs

Michael Diem

Donna Klein

Ricardo Attar

Sheri Moores

Kristen Picha

Alastair King

Mark L Anderson

Shalom Goldberg

Alexey Teplyakov

Rosa Cardoso

Tracy Spinka-Doms

Jill M Giles-Komar

Ellen Chi

Juan C Almagro

Gopalan Raghunathan

Ronald Swanson

Jill Carton

Johan Fransson

Hong Mimi Zhou

Shanrong Zhao

Wendy Cordier

Jinquan Luo

Sheng-Jiun Wu

Francois Gaudet

Yiqing Feng

Yingzhe Li

Glenn Mark Anderson

Jill Marie Mooney

Ronan McDaid

Benjamin J Harman

Jennifer Nemeth-Seay

Steven Pomerantz

Yiging Feng

Galla Chandra Rao

Leopoldo Luistro

Anderson Mark

Bryan Wang

Mark Anderson

Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

EGFR and C-met fibronectin type III domain binding molecules

PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Prostate specific membrane antigen binding fibronectin type iii domains

EGFR and c-Met fibronectin type III domain binding molecules

Provided herein are isolated CD3&#xd7;PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3&#xd7;PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.

Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof

Prostate specific membrane antigen binding fibronectin type III domains

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Cysteine engineered fibronectin type III domain binding molecules

EGFR and C-Met fibronectin type III domain binding molecules

The invention relates to a compositions and methods for generating and using pIX phage display libraries for producing non-antibody peptide or protein proteins or peptides using engineered hybrid phage vectors derived from pIX of M 13 phage

Engineered hybrid phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pIX of M13 phage

The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Engineered anti-IL-13 antibodies, compositions, methods and uses

The present invention relates to engineered antibodies immunospecific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.

Growing community of inventors

Spring House, PA, United States of America

Linus Hyun